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I. SOCIAL-DEMOGRAPHICS, HEALTH BEHAVIORS, AND TELOMERE

LENGTH IN MEXICAN AMERICANS: A COHORT STUDY
Recent studies using a prospective cohort design have suggested that telomere length in
peripheral blood leukocytes is not only a potential indicator of cellular aging that has
been linked to stressful life experience and health behaviors, but also a prognostic marker
for major chronic diseases; however, such study has never been done among adult
Mexican Americans. In this current study, we examined cross-sectional associations
among social-demographics, lifestyle behaviors, and relative telomere length (RTL) in
peripheral blood leukocytes, as well as longitudinal relationships among major chronic
diseases, weight gain, and RTL, among 12,792 Mexican Americans aged 20 to 85 years
in the Mano-A-Mano, a Mexican American Cohort. As expected, RTL was inversely
correlated with age (ρ=-0.15, p<0.001). In the multivariate analysis, we found that RTL
was positively correlated with levels of education (P=0.021), self-insurance (P=0.041),
body mass index (BMI) (P<0.001), and sleeping time per day (P for trend<0.001). In
5

contrast, RTL was inversely correlated with sitting time per day (P for trend =0.001). In
longitudinal analysis, we found that longer RTL was modestly but positively associated
with increased risks of diabetes (adjusted hazard ratio (adj.HR) =1.04, 95% conference
interval (CI) =1.01-1.08) and hypertension (adj.HR=1.03, 95% CI=1.00-1.08). Similar
but marginal association was observed for incident cancer (adj.HR=1.04, 95%
CI=0.99-1.10). Further stratified by cancer site, the significant association was observed
for lung cancer (adj.HR=1.21, 95% CI=1.00-1.46). In addition, longer RTL was a
positive predictor of at least 10% weight gain (adj.HR=1.03, 95% CI=1.00-1.05). In
summary, our results in Mexican Americans support the notion that telomere length is a
biological mechanism by which social demographics and health behaviors “get under the
skin” to affect health.
II. METHYLATION IN SERUM CELL-FREE DNA AND CPG-SNP WITH
BLADDER CANCER RISK
Epigenetic alterations are early events of cancers, including bladder cancer. In the present
study, we aimed to examine methylation profiles of circulating DNA in serum of bladder
cancer patients, in an effort to develop reliable DNA methylation signatures to diagnose
the disease. Firstly, we performed whole genome DNA methylation profiling with
Illumina Infinium HumanMethylation450 beadchip in 23 participants in a bladder cancer
case control study. 396 target cytosine-phosphate- guanine (CpG) sites were identified as
hypermethylated in cases compared with the controls. The top 5 candidate CpG sites
hypermethylated in cases during the screening phase were further validated by
6

pyrosequencing, in 100 bladder cancer patients (including 50 non-muscle invasive and 50
muscle invasive bladder cancers) and 50 healthy controls. Successful methylation data
were obtained for 4 of the selected CpG sites, located in genes of TTC23, WWOX,
ZNF624 and LOC2211122, respectively. Unfortunately, none of these 4 sites exhibited
differential methylation between cases and controls in this validation.

Interestingly,

there was a SNP rs8038732 (G>A) in the methylation site of gene TTC23. The GG
genotype showed near complete methylation, G/A heterozygotes half methylation, and
AA complete loss of methylation. This SNP is clearly a functional SNP because the G>A
transition almost completely knocks out methylation at this site.

It would be interesting

to see whether this SNP affect bladder cancer risk. However, this SNP was not genotyped
in our previously published genome-wide association study (GWAS). But, we found that
another SNP, rs1377267 (A>C), on the GWAS chip is in strong linkage disequilibrium
(r2=0.85) with rs8038732. Moreover, the SNP rs1377267 significantly associated with
the risk of bladder cancer in our GWAS study. Specifically, the heterozygous alleles (AC)
was associated with higher bladder cancer risk (OR=1.34, 95% CI=1.09-1.65), whereas
the homozygous alleles (CC) were marginally associated with lower risk of bladder
cancer (OR=0.78, 95% CI= 0.59-1.03). From this result, we could infer that rs8038732
has similar association with the risk of bladder cancer. Our study suggests that rs8038732
affects the risk of bladder cancer by removing a cytosine-phosphate-guanine (CpG)
dinucleotide and knocking out DNA methylation at this site. Loss of methylation may
increase the expression of TTC23, which is a potential oncogene.
7
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Project I: Social-demographics, health behaviors and telomere length in Mexican
Americans：a cohort study
Introduction
Telomeres consist of tandem DNA repeats and associated proteins that cap the
end of chromosomes and provide protection to eukaryotic chromosomes [1] [2]. As a
normal cellular aging process, telomere length decreases with age. However, how quick
telomeres shorten varies significantly among the population, and many factors, including
genetic, environmental, socio-demographic, cultural and behavioral factors [3-5], may
affect the rate of telomere length shortening. More importantly, how long the telomeres are
has significant public health and disease implication. Critically short telomeres may lead to
chromosomal instability and thus cause diseases [6]. On the other hand, cells with longer
telomeres may have prolonged cell life and higher chances of developing DNA damage
and chromosomal instability, thus being at high risk of tumorigenesis [7]. Current studies
have demonstrated links between telomere length and risk of major chronic diseases,
including cancer [8-10], type 2 diabetes [11], and cardiovascular disease [12, 13].

The link between low socioeconomic status (SES) and the development of
age-related chronic diseases has been widely observed [14-20]. Several theories have been
proposed and the common assumption is that the chronic stress associated with social
disadvantage causes wear and tear on the body, which promotes the declined rate of
physiological function [20, 21]. Such decline may affect leukocyte telomere length and
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further impact biological aging and other age-related chronic diseases. Studying the role of
leukocyte telomere length in stress, biological aging, and age-related chronic diseases is
particularly relevant to Mexican Americans. Mexican Americans are one of the
fastest-growing populations in U.S. [22]. Compared to non-Hispanic whites, Mexican
Americans tend to have lower SES, including lower income and homeownership, and less
education and access to health care [23]. On the other hand, Mexican Americans are
experiencing high burden of age-related chronic diseases, including cardiovascular
diseases and type 2 diabetes [24-27]. In addition, they have unique psychological, somatic,
and social stress associated with acculturation [28, 29]. Studies have shown that
acculturation confers risk for stress, and stress related diseases and poor health behaviors in
Mexican Americans [30-32].

Leukocyte telomere length may also be the link between unhealthy behaviors and
age-related chronic diseases [3, 33, 34]. Maintaining a healthy lifestyle, including keeping
a normal weight, regular physical activity, not smoking, and not heavy drinking, can
contribute to decrease the levels of inflammation and oxidative stress [34-38], which helps
to prevent chronic diseases [33, 34, 39, 40]. Studying health behaviors, age-related chronic
diseases, and leukocyte telomere length is particularly important for Mexican Americans
because 3 out of 4 Mexican Americans are either overweight or obese [41, 42]. In addition,
they participate in low levels of physical activity [43], and recent surveillance data show
only 44.6% met national physical activity recommendations [44].
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To date, the relationship among social demographics, lifestyle behaviors, and
leukocyte telomere length has not been investigated in any prospective cohort study of
adult Mexican Americans. Here, taking advantage of a large ongoing prospective Mexican
American Cohort study, we detected relative telomere length (RTL) in peripheral blood
leukocytes from 12,792 Mexican American study subjects, and investigated its
relationships with social demographics, lifestyle behaviors, and major chronic diseases at
baseline, and with the development of cancer, diabetes, and hypertension at follow-up.
Additionally, we studied whether RTL could predict prospective weight gain during
follow-up.
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METHODS AND MATERIALS
Study Population
The samples for the current study were recruited from participants in a large
population-based cohort of Mexican origin households recruited from Houston [45]. This
Mano a Mano cohort, an ongoing prospective cohort of 1st and 2nd generation Mexican
origin immigrant households in Houston, TX, initiated in July 2001 and maintained by
the Department of Epidemiology at the University of Texas MD Anderson Cancer Center
in Houston, Texas. A detailed description of the sampling and recruitment strategy has
been published previously [46]. Briefly, Participants was drawn by random-digit-dialing,
block walking in predominantly Mexican American neighborhoods, from community
centers and local clinics, or networking through currently enrolled participants [47] [48].
Once the identified eligible households agreed to participate in the study, then the written
informed consent would be obtained; the participants were interviewed by well-trained
interviewers using a structured questionnaire; the interview last ~45 minutes and was
conducted in Spanish or English; the epidemiological data collected by this questionnaire
included birthplace, residential history, social-demographic characteristics, lifestyle
behaviors, levels of physical activity, personal medical history, family history of chronic
disease, acculturation, and occupation exposure [49]. All the participants were followed
up through telephone annually; the study was approved by the institutional review board
of MD Anderson Cancer Center [46].
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Relative Telomere Length (RTL) Assessment
Genomic DNA was isolated from participants’ whole blood with the QIAamp
Maxi DNA kit from Qiagen (Valencia, CA). Isolated DNA samples were quantiﬁed by
Quant-iTTM PicoGreen®dsDNA Reagent and Kits from Invitrogen (Carlsbad, CA)
according to the manufacturer’s directions. The RTL was measured with a modified
method of real-time quantitative polymerase chain reaction (PCR), which was originally
set up by Cawthon [50, 51]. A detailed description of the experimental strategy has been
published previously [52-54]. Briefly, the ratio of the telomere repeat copy number (T) to
the single gene (human globulin) copy number (S) was detected, which was proportional
to the telomere length [54]. The mixture of PCR reaction (14 µl) consisted of 1 x SYBR
Green Master Mix (Applied Biosystems, Foster City, CA), 200 nmol/l Tel-1 primer
(5’-CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT), 200 nmol/l Tel-2
primer (5’-GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT), and 5 ng
genomic DNA; the PCR reaction mixture (14 µl) for HGB gene amplification was similar
except the primers- Hgb-1 primer (5’-GCTTCTGACACAACTGTGTTCACTAGC) and
Hgb-2 primer (5’-CACCAA CTTCATCCACGTTCACC); the thermal cycling conditions
were 1 cycle at 95oC for 10 minutes followed by 40 cycles at 95oC for 15 seconds and at
56oC (for telomere amplification) or 58oC (for HGB amplification) for 1 minute; the
HT7900 system (Applied Biosystems, CA) was used to perform the Real-time PCR，each
sample was detected in duplicates in a 384-well plate; in each assay, negative control,
positive control (Roche Applied Science, Pleasanton, CA), calibrator DNA, and a
17

standard curve were included; the standard deviations for the Ct values were set at 0.25
for all the samples; the standard curve with high coefficient of determination (R2≥0.99)
will be selected for further analysis; in addition, the acceptable coefficient of variation
were <3% for intra-assay and <5% for the inter assay [53].

Statistical Analysis
We used the statistical software package SAS, version 9.4 (SAS, Cary, NC) for
analysis. Although the relative telomere length data were not normally distributed, we
performed the analysis using both data with and without log transformation. We found
there was no significant difference in estimate of the relationships among
social-demographics, health behaviors, major chronic diseases, and RTL. Thus, only data
without log transformation were presented here. Differences in the distribution of
social-demographics, health behaviors, and major chronic diseases were evaluated by
Pearson χ2 test for categorical variables. Spearman correlation was used to assess the
relationship between age and RTL. In the univariate analysis, the general linear
regression analysis was used to compare RTL by the selected variable. Both age and
gender were adjusted as appropriate. Mediation analysis was performed to assess the role
of RTL between BMI and chronic diseases at baseline. In the multivariate analysis, the
general linear model was used. The social-demographic and health behavior variables
with P value less than 0.25 in the univariate analysis were included in the multivariate
analysis. For joint effect analysis, we created a social-behavioral score by including 2
18

SES related variables (education and self-insurance) and 2 lifestyle behaviors (sitting
time and sleeping time). For each variable, we created a binary high SES or healthy
variable, defined as at least high school education, having self-insurance, sitting less than
2 hours per day, and sleeping more than 6 hours per day, respectively. The
social-behavioral score ranged from 0 (low SES and no healthy behaviors) to 4 (high SES
and healthy behaviors). Multivariate analysis was used to assess the correlation between
the social behavior and RTL. The associations among incident cancer, diabetes,
hypertension

and

RTL

were

assessed

using

the

multivariable-adjusted

Cox

proportional-hazard regression model. RTL was analyzed as both a continuous and
categorical variable. For categorical variable, cutoff points were set at the quartile values
in the non-cancer study population. Adjusted Hazard ratio (HR) and 95% confidence
interval (CI) were estimated and co-variants were adjusted as appropriate.
Multivariable-adjusted Cox proportional-hazard regression model was also used to
examine whether RTL at baseline could predict at least 10% weight gain in the follow-up.
All statistical tests were 2-sided, and the value of statistical significance was set as 0.05.
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RESULTS
A total of 12,792 MA study subjects were included in the RTL analysis. Among
them, 614 were excluded for further analysis due to abnormal RTL value (outside of ±3
standard deviation of age adjusted mean RTL). Thus, a total of 12,178 study subjects
were included in further data analysis. Baseline social demographic characteristics,
immigration related variables, lifestyle factors, and major chronic diseases are presented
in Table 1. The mean and median ages of the population were 42 and 39 years old,
respectively. The majority of study subjects were women (79.56%) and married (or living
together) (77.00%). In this study, we used levels of education, health insurance, home
and vehicle ownership to assess SES. Only 40.60% of study subjects had at least high
school education. For health insurance, 49.66%, 46.23%, and 68.55% had self, partner,
and kids insurances, respectively. In terms of home and vehicle ownership, 45.96% and
78.41% owned a home and a vehicle, respectively. For immigration related variables, the
majority was born in Mexico (73.77%) and less acculturated (63.28%). Among Mexico
born study subjects, 29.53% arrived in U.S. younger than 20 years old and 46.39% have
lived in U.S. for more than 15 years. We included 6 lifestyle behaviors in the analysis,
namely cigarette smoking, alcohol consumption, BMI, sedentary behavior, sitting time,
and sleeping time. The majority of study subjects were overweight or obese (85.04%),
never smokers (71.80%), never alcohol drinkers (66.66%), and sedentary (79.06%). Over
a half of study subjects had more than 2 hours sitting time per day (53.42%). The
majority of study subjects had 7 to 8 hours sleeping time per day (60.36%). The most
20

prevalent chronic disease was hypertension (19.48%), followed by diabetes (15.27%),
gallbladder disease (8.83%), asthma (3.97%), cancer (2.65%), and kidney disease
(1.91%).

The mean and median of RTLs were 0.76 and 0.75, respectively. The range was
between 0.21 and 0.99. As expected, a significant inverse relationship between RTL and
age was observed (ρ=-0.15, p<0.001). For every one year increase in age, there was a
0.002 reduction in RTL. In the univariate analysis, we investigated the relationships
among baseline social-demographics, health behaviors, major chronic diseases, and RTL
(Table 1).
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Table 1. Distribution of selected socio-demographics, health behaviors, and major diseases and
RTL among 12,178 Mexican American study subjects
Relative telomere
Variables

Number of study subjects (%)

length

P value*

Age at enrollment
20-31

3,116 (25.59)

0.81

32-39

3,104 (25.49)

0.78

40-50

2,925 (24.02)

0.75

>50

3,033 (24.91)

0.72

Men

2,535 (20.44)

0.76

Women

9,866 (79.56)

0.76

married

9,365 (77.00)

0.76

Other

2,797 (23.00)

0.76

<High school

7,229 (59.40)

0.76

At least high school

4,941 (40.60)

0.77

Yes

5,498 (49.66)

0.77

No

5,574 (50.34)

0.76

Yes

4,227 (46.23)

0.77

No

4,917 (53.77)

0.76

Yes

6,502(68.55)

0.77

No

2,983(31.45)

0.76

Yes

5,025 (45.96)

0.76

No

5,909 (54.04)

0.76

Yes

8,558 (78.41)

0.76

No

2,356 (21.59)

0.77

8,973 (73.77)

0.76

<0.001

Gender

0.324

Marital Status
Married/living as

0.780

Education

0.069

Self insurance

0.004

Partner insurance

0.189

Kids insurance

0.264

Own home

0.539

Own car

0.618

Birth location
Mexico
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U.S.

3,191 (26.23)

0.76

0.221

Years lived in U.S. (for born in Mexico only)
<5

1,038 (11.57)

0.75

5-10

1,841 (20.52)

0.77

10-15

1,930 (21.51)

0.76

>15

4,162 (46.39)

0.77

<20

2,649 (29.53)

0.76

20-29

3,906 (43.55)

0.77

≥30

2,415 (26.92)

0.76

High

4,449 (36.72)

0.76

Low

7,666 (63.28)

0.76

Current

1,579 (12.99)

0.76

Former

1,848 (15.20)

0.76

Never

8,727 (71.80)

0.76

Current

2,770 (22.88)

0.76

Former

1,267 (10.46)

0.76

Never

8,071 (66.66)

0.77

Under/Normal weight (<25)

1,791 (14.96)

0.75

Overweight (25-29.9)

4,072 (34.00)

0.76

Obese (>30)

6,112 (51.04)

0.77

No

2,380 (20.94)

0.77

Yes

8,987 (79.06)

0.76

<2

4,784 (46.58)

0.76

2-3

2,817 (27.43)

0.74

>3

2,670 (26.00)

0.75

<=6

3,307 (28.96)

0.74

7-8

6,894 (60.36)

0.75

≥9

1,220 (10.68)

0.77

0.255

Age at arrival (for born in Mexico only)

0.242

Language acculturation

0.308

Cigarettes smoking status

0.882

Alcohol drinking status

0.244

BMI

<0.001

Sedentary behavior

0.052

Sit hours/day

<0.001

Sleep hours/day

0.001
23

Any Major Disease (prevalence)
Yes

7,298 (60.01)

0.77

No

4,864 (39.99)

0.75

Yes

2,372 (19.48)

0.78

No

9,805 (80.52)

0.76

Yes

1,859 (15.27)

0.77

No

10,317 (84.73)

0.76

Yes

1,075 (8.83)

0.79

No

11,102 (91.17)

0.76

Yes

483 (3.97)

0.77

No

11,694 (96.03)

0.76

Yes

323 (2.65)

0.84

No

11,855 (97.35)

0.76

Yes

232 (1.91)

0.82

No

11,945 (98.09)

0.76

0.013

High blood pressure
(prevalence)

<0.001

Diabetes (prevalence)

0.401

Gallbladder disease
(prevalence)

0.001

Asthma (prevalence)

0.729

All cancer (prevalence)

<0.001

Kidney disease (prevalence)

0.014

* Adjust for age and gender as appropriate

Among demographic characteristics, the most significant association was observed for
age category. As expected, we observed a significant trend of decreasing RTL with the
increasing age category from 20-31 to over 50 years old (p<0.001). Among SES related
variables, study subjects who had less than high school education had marginally shorter
RTL than those who had at least high school education (p=0.069). Study subjects who
had self-insurance had significantly longer RTL than those who did not (p=0.004). No
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significant association was observed between immigration related variables (including
birth location, acculturation, years lived in U.S., and age at arrival) and RTL.

For health behaviors, the most significant association was with BMI. We found a
significant positive relationship between BMI (as continuous variable) and RTL
(p<0.001). In the BMI categorical analysis, after adjusting for age and gender, RTL was
shortest among study subjects who were under or normal weight (0.75), median among
those who were overweight (0.76), and longest among those who were obese (0.77)
(p<0.001). When the study subjects were stratified by age categories, 20-29, 30-39, 40-49,
50-59, 60-69, 70-79, and 80 or more years old (Figure 1), the trend of RTL difference
among BMI categories was persistent for most of the age categories. More interestingly,
when we further compared the rate of RTL shortening by age among three BMI
categories, RTL shortening by age was seemingly quicker among those who were under
or normal weight than those who were overweight or obese, although the difference of
slope was not statistically significant (p=0.187). When we compared RTL difference
between those in 20-29 and those in 80 or more years old, the difference was 0.19 for
under or normal weight, 0.13 for overweight, and 0.085 for obese groups (P=0.005).
Significant relationships were also observed for sitting time and sleeping time. Study
subjects who had less than 2 hours sitting time per day had the longest RTL (0.76)
compared to those who had 2-3 hours (0.74) and more than 3 hours sitting time per day
(0.75) (P<0.001). RTL was positively associated with hours of sleeping per day. RTL
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was longest among those who slept at least 9 hours per day (0.77), median among those
who slept 7-8 hours per day (0.75), and shortest among those who slept no more than 6
hours per day (0.74) (P<0.001). In addition, those who were sedentary had marginally
shorter RTL than those who were not sedentary (0.76 vs 0.77, P=0.052).

0.85
0.8

Relative telomere length

0.75

Normal(18.5-24.9)
Overweight(25-29.9)
Obese(30+)

0.7
0.65
0.6
0.55
20-29 30-39 40-49 50-59 60-69 70-79
Age

80+

Fig. 1 Association of RTL and BMI in different age categories

For major chronic diseases at baseline, study subjects who had at least one of six major
chronic diseases (including hypertension, diabetes, gallbladder disease, asthma, cancer,
and kidney disease) had longer RTL than those who have no chronic diseases (RTL: 0.77
vs 0.75, p=0.013). When stratified by type of chronic disease, significant difference was
remained for hypertension (P<0.001), gallbladder disease (P<0.001), cancer (P<0.001),
and kidney disease (P=0.014). In the mediation analysis, we examined the potential
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mediating role of RTL on the association between BMI and major chronic diseases. The
significant effect was observed for hypertension and gallbladder disease. About 5.25% of
the association between BMI and hypertension, and 5.13% of the association between
BMI and gallbladder disease were mediated by RTL (P=0.001 and 0.037, respectively).

Next, we included all social-demographics and health behaviors with p value ≤
0.25 in the univariate analysis (from Table 1) into a multivariate model. The results were
presented in Table 2. BMI, as a continuous variable, was positively associated with RTL
(P<0.001). Compared to study subjects with lower education level, those with at least
high school education had significantly longer RTL (P=0.021). Compared to those who
slept 6 or less hours per day, those who slept 7-8 and more than 8 hours had significantly
longer RTL (P=0.003 and 0.001, respectively). RTL was also longer among those who
had self-insurance than those who had no self-insurance (P=0.041). On the other hand,
RTL was significantly inversely associated with age (P<0.001), and RTL was shorter
among those who sat more than 3 hours per day than those who sat less than 2 hours per
day (P<0.001).
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Table 2. Multivariate regression analysis of RTL on social-demographics and health behaviors
Variables
age
Gender (women vs men)
BMI
Education (≥ high school vs < high school)
Birth place (U.S. vs Mexico)
Ever vs never smokers
Ever vs never drinkers
Sleep time (≤6 hours/day)
7-8 hours/day
≥9hours/day
Sitting time (<2 hours/day)
2-3 hours/day
>3 hours/day
Sedentary lifestyle (yes vs no)
Self-insurance (yes vs no)
Intercept
R2

Estimate
-0.003
0.002
0.002
0.013
0.009
-0.008
0.009

Standard Error
0.0002
0.008
0.0005
0.006
0.007
0.007
0.007

P value
<0.001
0.804
<0.001
0.021
0.197
0.230
0.220

0.028
0.039

0.009
0.010

0.003
0.001

-0.003
-0.026
-0.0003
0.012
0.838
0.026

0.008
0.007
0.007
0.006
0.021

0.674
<0.001
0.965
0.041
<0.001

To assess the potential joint effect of SES and health behaviors on RTL, we
created a social-behavioral score by including 2 SES related variables (education and
self-insurance) and 2 lifestyle behaviors (sitting time and sleeping time). For each
variable, we created a binary high SES or healthy variable, defined as at least high school
education, having self-insurance, sitting less than 2 hours per day, and sleeping more than
6 hours per day, respectively. The social-behavioral score ranged from 0 (low SES and no
healthy behaviors) to 4 (high SES and healthy behaviors). We investigated the association
between the social-behavioral score and RTL (Figure 2). In general, with the score
increased from 0 to 4, RTL gradually increased (p<0.001). For study subjects with
social-behavioral score 0, 1, 2, 3, and 4, their mean RTL was 0.71, 0.73, 0.75, 0.77, and
0.78, respectively.
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Fig. 2 Association between the social-behavioral score and RTL

To assess whether RTL was a predictor of chronic diseases, we analyzed the relationships
between RTL and incident cancer, diabetes, and hypertension during the follow-up. A
total of 287 incident cancer cases were observed and confirmed during the follow-up.
Overall, RTL was not significant different between incident cancer cases and non-cancer
controls (0.77 V.S. 0.76, p=0.555). In the multivariable-adjusted Cox proportional-hazard
regression model, using RTL as a continuous variable, we found that longer RTL was
marginally associated with increased risk of overall cancer (adjusted HR=1.04,
95%CI=0.99-1.10) (Table 3).
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Table 3. Risk of incident cancer associated with RTL
RTL

Cancer Cases

(continuous variables, unit=0.1)
All cancer
Breast cancer (women only)
Lung cancer
Cervical cancer (women only)
Liver cancer
Prostate cancer (men only)

Non-cancer

Adj. HRs (95% CI)*

P value

1.04 (0.99-1.10)
1.01 (0.91-1.12)
1.21 (1.00-1.46)
0.96 (0.76-1.23)
1.01 (0.78-1.31)
1.09 (0.86-1.36)

0.111
0.867
0.049
0.766
0.960
0.898

controls
287
68
18
11
12
20

10,340
8,414
10,605
8,465
10,611
2,120
All Cancer

By quartile

N (%)

N (%)

Adj. HRs (95% CI)*

1st
71 (24.74)
2,615 (25.29)
reference
2nd
90 (31.36)
2,760 (26.69)
1.15 (0.84-1.58)
3rd
72 (25.09)
2,468 (23.87)
1.20 (0.86-1.67)
4th
54 (18.82)
2,497 (24.15)
1.41 (1.00-2.03)
P for trend
*adjusted for age, obesity status, alcohol drinking, cigarette smoking, and education.

P Value
0.372
0.279
0.049
0.064

When stratified by top incident cancer site, the only significant association observed was
with lung cancer (adjusted HR=1.21, 95% CI=1.00-1.46). In further quartile analysis,
compared to individuals who had shortest RTL (1st quartile), those who had longer RTL
(2nd, 3rd, and 4th quartiles) had an increased risk of overall cancer. However, the only
significant association was observed among those in the 4th quartile with the highest RTL
(adjusted HR=1.41, 95% CI=1.00-2.03). The p for trend was 0.064. During the follow-up,
a total of 648 and 878 study subjects were diagnosed with diabetes and hypertension.
Overall, RTL was significantly positively associated with risks of incident diabetes and
hypertension (diabetes: adjusted HR=1.04, 95% CI=1.01-1.08; hypertension: adjusted
HR=1.03, 95% CI=1.00-1.06) (Table 4).
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Table 4. Risk of incident diabetes and high blood pressure associated with RTL
RTL

Diabetes

Non-diabetes

HR(95%CI)

P value

N (%)

N (%)

1st

152 (23.46)

2,075 (24.82)

ref.

2nd

211 (32.56)

2,165 (25.89)

1.23 (1.00-1.53)

0.055

3rd

144 (22.22)

2,025 (24.22)

1.00 (0.79-1.26)

0.988

4th

141 (21.76)

2,096 (25.07)

1.31 (1.03-1.67)

0.026

quartile

P for trend

0.167

Continuous variable (unit=0.1)

1.04(1.01-1.08)

0.021

High blood

No high blood

Pressure N (%)

Pressure N (%)

1st

227 (25.85)

1,931 (25.14)

ref.

2nd

257 (29.27)

1,985 (25.84)

0.93(0.77-1.11)

0.422

3rd

217 (24.72)

1,828 (23.80)

0.93(0.77-1.13)

0.474

4th

177 (20.16)

1,937 (25.22)

1.22(1.01-1.50)

0.044

quartile

P for trend
Continuous variable (unit=0.1)

0.123
1.03(1.00-1.06)

0.049

*adjusted for age, sex, obesity status, alcohol drinking, and education.

In further quartile analysis, we found that study subjects who had the longest RTL (4th
quartile) had a 1.31-fold increased risk of diabetes (adjusted HR=1.31, 95% CI=1.03-1.67)
compared to those who had shortest RTL (1st quartile). Similarly, we observed that study
subjects who had highest RTL (4th quartile) had 1.22 fold increased risk of hypertension
(adjusted HR=1.22, 95%CI=1.01-1.50) compared to participants who had lowest RTL (1st
quartile). Last, in a subset of study subjects with multiple weight data during follow-up,
we explored whether RTL could predict weight gain during the follow-up (Table 5).
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Table 5. Risk of weight gain(>=10%) and RTL
age

HR(95%CI)
0.97 (0.97-0.98)

P value*
<0.001

Gender: women vs men

1.49 (1.17-1.91)

0.001

BMI

0.95 (0.94-0.96)

<0.001

0.73 (0.63-0.85)

<0.001

acculturation: high vs low

1.20 (1.02-1.41)

0.026

Birth place: U.S. vs Mexico

0.83(0.69-1.00)

0.049

RTL (0.1 per unit)

1.03 (1.00-1.05)

0.035

marital status:

married vs other

Using at least 10% weight gain compared to the baseline weight during the follow-up
as the event, we performed multivariate regression analysis. The significant variables in
the final model included age at baseline, gender, baseline BMI, marriage status,
acculturation, birth place, and RTL. RTL was a positive predictor of at least 10% weight
gain during the follow-up (adjusted HR=1.03, 95%CI=1.00-1.05). In addition, older age,
married (or living together), high BMI, and born in U.S. were associated with less likely
to gain at least 10% weight (age: adjusted HR=0.97, 95%CI=0.97-0.98; marriage status:
adjusted HR=0.73, 95%CI=0.63-0.85; BMI: adjusted HR=0.95, 95%CI=0.94-0.96; and
birth place: adjusted HR=0.83, 95%CI=0.69-1.00, respectively). Being women and
higher acculturated were associated with more likely to gain at least 10% weight (gender:
adjusted HR=1.49, 95% CI=1.17-1.91; and acculturation: adjusted HR=1.20, 95%
CI=1.02-1.41).
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Discussion
The associations among social-demographics, health behaviors, and telomere
length have rarely been studied in adult Mexican Americans. The only published study
was from the National Health and Nutrition Examination Survey (1999-2002), which
includes 1,377 Mexican Americans [20]. In that study, the only significant factor
correlated with RTL was age. In our current study, with 12,792 Mexican Americans aged
20 to 85 years, in the cross-sectional analysis, we found that lower SES (measured by low
education levels and without self-insurance) was significantly associated with shorter
RTL. In addition, we observed RTL was positively correlated with BMI, sleeping time,
and several major chronic diseases, and negatively correlated with age and sitting time.
Then, in the longitudinal analysis, we found longer RTL was a predictor for all cancer,
diabetes, hypertension, and weight gain, although the associations were modest to
marginal.

Socioeconomic disparities in chronic diseases are well-documented, but little is
known about the mechanisms [20]. In the current study, we use indicators of SES
including education attainment, health insurance, home and vehicle ownership. We
observed an inverse relationship between levels of SES and RTL. Study subjects with
less than high school education had shorter RTL than those who had at least high school
education (P=0.021). Similarly, study subjects with no self-insurance had shorter RTL
than those who had self-insurance (P=0.041). We did not find a significant association
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between home and vehicle ownership and RTL. Our results are consistent with several
previous studies. For example, Needham et al. found that telomere length was positively
associated with education level (P<0.01) [20]. However, the significant relationship was
only observed among Caucasian American study subjects, not among African and
Mexican Americans. The only significant relationship reported among Mexican
Americans was from Multi-Ethnic Study of Atherosclerosis (MESA), which evaluated
the relationship between SES and telomere length among 963 U.S. adolescents, including
510 Mexican American adolescents [20, 55]. In that study, telomere length was found
negatively associated with current home ownership and father’s education [20].

Health behavior is a major determinant of chronic disease risk in most of the developed
countries [33, 34, 39, 56]. Epidemiological and basic science studies have shown that
unhealthy lifestyle including cigarette smoking, heavy drinking, sedentary behavior, and
obesity could increase stress levels, decrease immune function, and deteriorate
physiological condition [57-62]. In the current study, we found inverse relationships
among sitting time, sleeping time, and RTL, and a positive relationship between BMI and
RTL. No significant relationship was observed among cigarette smoking, alcohol
drinking, sedentary behavior, and RTL. The relationship among sedentary behavior,
sitting time, and RTL has been investigated previously [6, 20, 63-70]. The results are still
limited and inconsistent. For example, Sjögren et al. found

sitting time was associated

with longer telomere in sedentary, overweight 68-year-old participants [70]. Using data
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from Nurses’ Health Study, Du et al. reported that sitting time and sedentary behavior
were not associated with leukocyte telomere length [6]. However, they found that longer
telomeres are associated with moderate to vigorous amounts of physical activity [6].
Much of the discrepancy among different studies may be due to differences in study
population, such as race, age, occupation, and sample size.

One intriguing but puzzling finding from this study is the positive relationship
between BMI and telomere length. In a recent systematic review and meta-analysis of 29
existing studies, Muezzinler et al. concluded an inverse association between BMI and
RTL in adults [71]. However, in the Genetic Epidemiology Research Study on Adult
Health and Aging (GERA) with 100,000 study subjects presented in 2012 American
Society of Human Genetic Annual meeting, Schaefer et al. reported that BMI was
positively correlated with telomere length in saliva DNAs, which is consistent with our
finding. To eliminate the potential age effect, we stratified the study subjects based on
their age categories, and we found study subjects in the obese group had steadily longest
telomere length and those in the normal weight group had consistently shortest telomere
length. More interestingly, the difference of telomere length by BMI status was becoming
larger with the age increased. In studying the relationship between RTL and perspective
weight gain, we found that long RTL was associated with higher likelihood of gaining at
least 10% weight compared to the baseline. Our observation is consistent with the results
from the Health ABC study, in which Njajou et al. reported that telomere length was
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positively associated with both % body fat and BMI in 7- year follow-up [72]. Clearly,
more work is still needed to study the underlying molecular mechanisms between BMI
and RTL.

The relationship between RTL and major chronic diseases (both prevalent and
incident) was another piece of interesting finding. In cross-sectional analyses, longer RTL
was associated with increased prevalence of overall major chronic diseases as well as
several individually, including hypertension, gallbladder disease, cancer, and kidney
disease. In prospective analyses, longer RTL was associated with modestly to marginally
increased risks of diabetes, hypertension, overall cancer, and lung cancer. The
relationship between RTL and cancer has been studied extensively in both case control
and cohort settings [9, 10, 54, 73-87]. However, the results are inconsistent. One of the
exceptions might be lung cancer. In a recent pooled analysis, Seow et al. found that
telomere length was positively associated with higher risk of lung cancer [87]. Findings
were consistent across the three cohorts, PLCO trial, ATBC trial, and SWHS. Our result
is consistent with those findings. Although we do not know the exact biological
explanation, upon exposure to carcinogens, cells with longer telomeres may be less likely
to enter senescence or apoptosis. Their survival could increase their chance to have
extended carcinogen exposure and thereby increase the risk of developing genetic
abnormalities.
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However, the relationship among diabetes, hypertension, and RTL is puzzling. In
a recent meta-analysis study, Zhao et al. found that shortened telomere length was
significantly associated with an increased risk of type 2 diabetes (OR=1.29, 95% CI:
1.11-1.14) [11]. Similar association was also observed between shortened telomere length
and risk of hypertension [88]. One limitation in our study is that the incident diabetes and
hypertension cases were self-reported and we did not separate type 1 from type 2 diabetes.
Therefore misclassification may somehow contribute to the discrepancy. In addition, the
observed associations in our study are modest at best. Apparently, more studies are
needed to further clarify the associations.

There are several limitations in this study. First, the number of incident cancer,
diabetes, and hypertension is still small, especially for cancer. This limits our statistical
power to detect the associations. Thus, we need to be very cautious to interpret our
findings. Second, the analysis of SES and health behavior in relation to RTL is
cross-sectional. The findings do not tell us the timing of the effect. Longitudinal data
would be necessary to analyze the rate of telomere shortening. Finally, the exposure of
stress was not directly assessed [20].
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Conclusion
The relationships among SES, health behavior, chronic diseases and telomere length have
been studied previously [3, 33]. However, such study has never been comprehensively
investigated among adult Mexican Americans. This study fills the gap. Among 12,792
Mexican Americans, we found that RTL is significantly affected by SES and health
behavior. In addition, we found longer RTL is a predictor of lung cancer, diabetes,
hypertension and weight gain. Together with the results of other studies in different
populations and different races, our study suggests that RTL is one mechanism by which
social conditions and health behaviors affect human health.
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Project II: Methylation in serum cell-free DNA and CpG-SNP with bladder cancer
risk
INTRODUCTION
Bladder cancer has the fifth highest incidence rate of all malignancies in the
United States, with high recurrence rates [89-91]. In most cases, bladder cancer appears
as a non–muscle-invasive urothelial carcinoma [92]. Early detection of bladder cancer is
critical for increased chance of bladder preservation and improved overall survival.
Biomarkers play an important role in the early detection as they are the early events in the
tumorigenesis [93]. The ideal biomarker must be reliable, inexpensive, minimally
invasive, specific and sensitive to the disease [93, 94]. We are interested in developing
blood-based markers for the early detection of bladder cancer.

Circulating cell free DNA
The presence of tumor DNA in circulating blood (plasma or serum) has been
documented dating back to 1977 [95]. Cell-free DNA (cfDNA) was thought to be
released from either apoptotic or necrotic cancer cells, from direct secretion or as a
byproduct of phagocytosis from macrophages or other scavenger cells [95, 96]. With
recent advances in next generation sequencing (NGS) technology, cfDNA has been
explored extensively for its potential application to cancer detection [97]. In general, the
studies of cfDNA as cancer biomarkers focus on monitoring the presence of methylation,
aberrant tumor DNA mutation, microsatellite alternations, and mitochondria DNA in
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blood circulation [96, 97]. In this current study, we are going to focus on aberrant
methylation in circulating cell free DNAs.

DNA Methylation
In general, DNA methylation is thought to be an early event in tumorigenesis and
has therefore been proposed as a potential early cancer detection marker [98, 99]. To date,
accumulating data have shown that DNA methylation could be used to evaluate cancer
risk [100-102], predict patients’ prognosis [91, 101-103], and evaluate the response to
chemotherapeutic drugs [102, 104]. Mostly, DNA methylation occurs at a cytosine in a
CpG dinucleotide, by adding a methyl group to the number 5 carbon of the cytosine
pyrimidine ring [105]. Aberrant DNA methylation has been associated with
tumorigenesis as a consequence of the alteration it causes in gene expression [98, 106];
with hypermethylation associated with gene s, and hypomethylation with gene activation
[107]. Meanwhile, DNA methylation detection is relatively easy due to PCR-based
methods, which can compensate for the low content limitation [93], suggesting that
methylation of circulating DNA may become a biomarker for cancer diagnosis [93, 94,
105].

CpG-SNP
single-nucleotide polymorphisms in CpG sites are referred as CpG-SNPs. About
34% of the C/T or G/A autosomal SNPs identified by the second-phase HapMap database
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are located within a CpG site [105, 108], and some of these CpG SNPs have been related
with diseases [105, 109-112]. CpG-SNP would be a potential molecular mechanism
through which SNPs influence a phenotype of disease [105].
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METHODS AND MATERIALS
Study design
An outline of the study design is shown in Figure 3. Firstly, whole-genome serum
DNA methylation profiling was performed using the Infinium HumanMethylation450
BeadChip array (Illumina). 23 samples were included (15 cases and 8 controls) in the
screening. We found 396 significantly hypermethylated

CpG sites in cases and selected

the top 5 for validation by pyrosequencing in 150 samples (50 controls, 50 non-muscle
invasive and 50 muscle invasive bladder cancer patients).

Fig. 3 Flow chart of the study design

Study population and epidemiologic data
The study population has been described elsewhere [52, 113-115]. Briefly, the
population consisted of patients with newly diagnosed and histopathologically confirmed
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bladder cancer accrued at the University of Texas MD Anderson Cancer Center and
Baylor College of Medicine. The Controls were healthy individuals without a prior
history of cancer (except nonmelanoma skin cancer) [116], which were selected from a
large control pool recruited through a collaboration with the Kelsey-Seybold Clinic, the
largest private multi-specialty physician group in Houston [117]. Informed consents were
obtained from all the participants before collection of epidemiologic data and blood
samples. Epidemiologic and demographic data were collected through in-person
interviews by trained MD Anderson interviewers. All subjects were interviewed with a
structured questionnaire [118]. All studies were approved by the Institutional Review
boards of MD Anderson, Baylor College of Medicine, and Kelsey-Seybold Clinic [119].

Sample collection
All study participants signed informed consent and underwent an in-person
interview by trained MD Anderson staff with a structured questionnaire that elicited
information on epidemiologic data, including demographic characteristics, medical
history and smoking history [120]. Immediately after each interview, a 40-mL peripheral
blood sample was drawn. About 10 ml was drawn into a red top serum-separating tube,
processed for serum extraction within 2 hours, and then transferred into liquid nitrogen
tanks for long-term storage [120].

Circulating cell-free DNA Isolation
43

Cell-free circulating DNA was extracted from 1 ml of the serum with QIAamp
Circulating Nucleic Acid Kit from Qiagen (Hilden, Germany) according to the
manufacturer’s instructions. The final elution volume was 20 µl and extracted DNA was
quantified by NanoDrop ND-1000 spectrometer (Thermo Scientific, DE).

Bisulﬁte treatment of DNA
For samples used in chip screening, DNA was treated by bisulfite using EZ DNA
Methylation Kit (Zymo Research, Orange, CA) following the manufacturer’s protocol. In
brief, 1 µg of DNA was treated with sodium bisulfite, through which all unmethylated
cytosines were converted to uracils, but leaving methyl-cytosines unaltered; after
purification, the cfDNA obtained was dissolved in 10 µl of TE buffer and this modified
DNA was quantified by NanoDrop ND-1000 spectrometer (Thermo Scientific, DE); the
efficiency of cfDNA recovery after bisulfite treatment was around 55% [121]. After
bisulfite conversion, each sample was amplified, fragmented by enzymes, and hybridized
to the Illumina Infinium HumanMethylation450 BeadChip [122].

For samples analyzed by pyrosequencing, 800 ng of genomic DNA was
bisulfite-treated with EZ DNA Methylation-Gold Kit (Zymo Research, Irvine, CA)
according to the manufacturer’s protocol. To improve the efficiency of DNA elution, the
purification columns were stored overnight in M-Elution Buffer at 4oC prior to
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centrifugation. The samples were eluted in 40 µl of M-Elution Buffer, and 2 µl
(equivalent to 25 ng of bisulfite-modified DNA) was used for each PCR reaction.

Whole-Genome DNA methylation Profiling
Whole-genome serum DNA methylation profiling was performed on 23 serum
samples

(15

bladder

cancer

patients

and

8

controls)

using

the

Infinium

HumanMethylation450 BeadChip (Illumina) according to the manufacturer’s standard
protocols. This BeadChip covers more than 485,000 methylation sites, located in 99% of
RefSeq genes distributed across the promoter, UTR regions, first exon and gene body,
and 3’-UTR regions [122, 123]. Samples were bisulfite converted using the EZ DNA
methylation kit according to the manufacturer’s protocol. Controls on the array were used
to track the bisulfite conversion efficiency. The Infinium® HumanMethylation450
BeadChip array (Illumina Inc., San Diego, CA) was used to measure genome-wide CpG
methylation levels using beads with specific probes designed to target individual CpG
sites on bisulfite-converted genomic DNA [124].

Methylation analysis with pyrosequencing
The subsequent pyrosequencing analysis was done at the DNA Methylation
Analysis Core, The University of Texas MD Anderson Cancer Center. Primers of
pyrosequencing PCR and sequencing for the individual CpG sites were designed for the
forward strand with Pyromark Assay Design SW 1.0 software (Qiagen, Hilden,
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Germany), the reverse primer was biotin labeled at the 5’- end [125]. The primer
sequences are shown in Table 6.
Table 6 Information of Pyrosequencing PCR and sequencing primers
Oligo Name

Sequence 5' to 3'

Sequence to analyze

PCR
Product
Size (bp)

CG26853071/ GAGGTTGGTTTAGTGGAAGTAAT

TGGGGYGTTGYGGAAGTTTTTG

F1

GGTAGAAA ATGAAA

141

CG26853071/ [Btn]AACAATTTTCATTTTCTACCCAA
Rbio2

AAACTTC

CG26853071/ AGTTAGTTTTTGTTAATTTTGTGT
S3
CG05276469/ GTTAGGTTGTTTTAGGGATTGG

YGTAGTTTTTTGTYGG

113

1

F

CG05276469/ [Btn]CCCCCCAACTAACCCTACCCA
Rbio2
CG05276469/ TTGTTTAGAGGGGTTTAG
S3
CG01630032/ GTGTTTGAGATTAAGATTTATTTGGT TAGGYGAGTGGAGGGGAGTTT
F1

AAGT

177

TGTTAGGTA

CG01630032/ [Btn]AACAAAACTCCCCTCCACT
Rbio2
CG01630032/ AAAGTAGAAATTAATTTTAATGATT
S3
CG25576961/ TTAGTTTATTGTGTAAAATGTGGTTA GGGYGGGGGAGA
1

F

208

GAG

CG25576961/ [Btn]AACCCCATCTACCACCTAAACTC
Rbio2

TTACA

CG25576961/ GAGGTTAGGATTAGTGG
S3
1. Forward primer for pyrosequencing PCR
2. Reverse prime with biotin label for pyrosequencing PCR
3. Sequencing primer
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A sequencing primer is identified within 1 to 5 base pairs near the CpG site of
interest, with an annealing temperature of 40 ± 5 oC. After that, forward and reverse
primers are identified upstream and downstream to the sequencing primer, with a target
annealing temperature ranging from 50 oC to 60 oC and amplicon product size ranging
from 100bp to 200bp.

Gradient PCR was used to detect the optimal annealing

temperatures for these primers. Controls for high methylation (SssI-treated DNA), low
methylation (WGA-amplified DNA), partial methylation (equimolar mixture of
SssI-treated and WGA-amplified DNA) and no-DNA template were included in each
reaction. For regions that were composed of mostly A and T bases, and additional control
of WGA-amplified DNA that was subsequently SssI-treated prior to bisulfite conversion
was also included, to account for biased representation of those regions in the whole
genome amplified genome.
PCR reactions were performed in a total volume of 15 µl, which was used for the
following pyrosequencing reaction (Table 7, 8). This method was previously described
[126]. In brief, streptavidin-sepharose high-performance beads (GE Healthcare Life
Sciences, Piscataway, NJ) were used to purify the PCR product. In addition,
co-denaturation of the biotin-labeled PCR products and sequencing primer was
performed following the guide of

PSQ96 sample preparation. Sequencing was

conducted on a PSQ HS 96 system (Biotage AB, Uppsala, Sweden) with the reagents of
PyroMark Gold Q96 CDT (Qiagen, Hilden, Germany) according to the manufacturer’s
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instructions. The methylation level was calculated using the Pyro-Q CpG 1.0.9v software
(Biotage AB, Uppsala, Sweden) [126].
Table 7. System of PCR reaction
PCR Reaction

Volume (µL)

Bisulfite DNA

2

2x Zymo Reaction Buffer

7.5

dNTP Mix (25mM each)

0.15

F primer (10uM)

0.3

R primer (10uM)

0.3

Zymo Taq

0.12

ddH 2 O

4.63

Table 8 PCR Cycling conditions
Step

Temp (oC)

Duration

1

95

10 m

2

95

30 s

3

53

30s

4

72

30s

5

Repeat (steps 2-4) 44 times (or 49 times, for CG6961)

6

72

7m

7

12

infinite

Identification of proxy SNPs
The analysis of proxy SNP was done by SNAP (SNP annotation and proxy)
search [127] [30]. The search was based on genotype data released by the 1000 Genomes
project and International HapMap Project. Inclusion criteria for LD (linkage
disequilibrium) SNPs were set as an r2 threshold >0.8 from pairwise LD calculations and
a distance limit of 500 kb from the query SNP [105].
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Genotyping
The method of genotyping has been described before [115]， the primary screen
was performed using the Illumina HumanHap 610 chip.

Statistical Analysis
Bead Studio Methylation Module software (Illumina) was used to analyze the
different methylation levels among different samples and groups [128]. The STATA
software (STATA Corp., College Station, TX) was used for all the statistical analyses.
Student’s t- test was used to assess differences in DNA methylation levels between cases
and controls. Differences in host characteristics between cases and controls were assessed
by X2 test for categorical variables (sex, smoking status, etc.) and the Student’s t test for
continuous variables (age). Unconditional multivariate logistic regression was performed
with adjustment for covariates to calculate odds ratios and 95% confidence intervals (CI).
All P values were two-sided, and the significance cut-off point was set as 0.05.
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RESULTS
Whole genome DNA methylation profiling
In our study, circulating cell free DNA from serum samples of 23 patients (7
NMIBC, 8 MIBC, and 8 healthy controls) were used for whole-genome methylation
profiling with Illumina Infinium HumanMethylation450 beadchip array. The methylation
statuses of more than 485,000 CpG sites were assessed. Prior to further analyses, probes
failed in any one of the 23 samples and probes in sex chromosomes were removed [128]
. As described before [129, 130], probes with β values being ≤0.2 or ≥0.8 in all
samples were also excluded [128]. As a result, we got 275,054 probes for the further
analysis, and obtained huge amount of CpG sites differentially methylated in bladder
cancer patients compared with the healthy controls. Thus, we tried to narrow down the
candidates by selecting those sites that were significantly hypermethylated in cases with
∆β> 0.2 (∆β=βcase-βcontrol). As a result, we got 396 candidate CpG sites which are
hypermethylated in cases compared with the healthy controls.

Validation of hypermethylated CpG sites by pyrosequencing
Five out of the hypermethylated 396 CpG sites from the microarray (Table 9)
were selected for validation by bisulfite modification-based pyrosequencing assays in 150
serum samples (50 NMIBC, 50 MIBC, and 50 Controls). The characteristics of
participants were summarized in Table 10.
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Table 9 Five CpG sites are hypermethylated in cases in the screening
Target ID

DNA Methylation Level ( β value)

Gene Symbol

P value

Case (N=15)

Control(N=8)

Mean(SD)

Mean (SD)

Δβ=Case β -Control β

cg26853071 LOC221122

0.72 (0.08)

0.40 (0.30)

0.32

0.005

cg20823859 OVGP1

0.56(0.17)

0.27 (0.17)

0.29

0.001

cg25576961 TTC23

0.38(0.17)

0.11 (0.05)

0.27

0.001

Cg05276469 ZNF624

0.59(0.12)

0.38(0.19)

0.21

0.003

cg01630032 WWOX

0.54(0.07)

0.34(0.07)

0.20

0.005
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Table 10. Host characteristics of participants in validation by pyrosequencing
Overall

Cases

Variables
Case (n=100)

Control
(n=50)

p

NMIBC

MIBC (n=50)

p

68.40( 9.11)

69.22( 7.92)

0.632

(n=50)

Age (y)
Mean(SD)

68.81( 8.51)

68.94( 8.13) 0.929

n (%)

n (%)

n (%)

n (%)

Male

90(90.00)

45(90.00)

45(90.00)

45(90.00)

Female

10(10.00)

5(10.00)

5(10.00)

5(10.00)

Never

25(25.00)

20(40.00)

12(24.00)

13(26.00)

Ever

75(75.00)

30(60.00) 0.059

38(76.00)

37(74.00)

Yes

7(14.00)

10(20.00)

No

43(86.00)

40(80.00)

Yes

18(36.00)

1(2.00)

No

32(64.00)

49(98.00)

Gender
1

1

smoking status
0.817

Death
0.424

Recurrence
<0.001

Progression
Yes

15(30.00)

5(10.00)

No

35(70.00)

45(90.00)

0.012

Treatment
iBCG

21(42.00)

mBCG

29(58.00)

TUR+cystectomy
TUR+cystectomy+chemotherapy

7(14.00)
14(28.00)

TUR+chemotherapy

6(12.00)

TUR

4(8.00)

Others

19(38.00)

Successful DNA methylation data were generated for 4 of the 5 CpG sites, located
in genes of WWOX, LOC2211122, ZNF624 and TTC23 (Figure 4). For these 4 CpG
sites, all the data passed the quality controls built into the analysis.
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Fig. 4 Successful DNA methylation data were generated for 4 of the 5 CpG sites

There were two methylation sites in gene ZNF624, both of which were
hypomethylated (Figure 5), so we used the average of methylation levels at the two sites
for each sample for analysis.

Fig. 5 Distribution of methylation levels of gene ZNF624 in different methylation sites

For gene WWOX, there is a SNP in the methylation site with a minor allele
frequency (MAF) less than 0.01, which was ignored. In addition, there is a SNP
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rs8038732 (G>A) with an MAF more than 0.42 in the methylation site of gene TTC23.
The minor allele (A allele) would cause differential methylation by eliminating the CpG
site, so the samples were grouped and analyzed according to the genotype of rs8038732.
Unfortunately, none of these 4 sites exhibited differential methylation between cases and
controls in our validation (Table 11, 12)

Table 11. Association of methylation levels of candidate target genes and bladder cancer
Gene

Methylation %

Methylation %

Cases (N=100)

Control(N=50)

Mean (SD)

Mean (SD)

WWOX

43.31 (22.5)

ZNF624

LOC221112

NMIBC (N=42)

MIBC (N=42)

P

Mean (SD)

Mean (SD)

P

41.45 (21.27)

0.656

43.24 (21.58)

43.39(23.59)

0.976

5.45 (1.92)

5.34 (1.83)

0.760

5.51 (1.73)

5.4(2.11)

0.789

91.11 (10.72)

91.1 (5.00)

0.995

90.37(14.62)

91.85(4.18)

0.531

Table 12. Association of methylation levels of TTC23 and bladder cancer
Gene

Genotype Case (n=100)

TTC23 rs8038732

Methy%

control (n=50)

NMIBC (n=50) MIBC(n=50)

Methy%

Methy%

n Mean(SD)

n Mean(SD)

GG

26

91.48(4.20)

14 91.37(3.04) 0.93

16 92.95(2.28) 10 89.14(5.52) 0.055

GA

53

47.67(6.80)

25 45.88(8.25) 0.313

25 46.92(9.02) 28 48.35(3.97) 0.450

AA

21

1.74(2.18)

11 2.41(2.47) 0.431

9

(G>A)

p

n Mean(SD)

Methy%

2.27(2.88)

n Mean(SD)

12 1.34(1.49)

P

0.346
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CpG-SNP rs8038732 and methylation level of gene TTC23
Interestingly, the methylation level of TTC23 was associated with the genotype
of SNP rs8038732 (G>A). As shown in Figure 6, the GG genotype showed near
complete methylation, G/A heterozygotes half methylation, and AA genotype complete
loss of methylation. This SNP is clearly a functional SNP because the G>A transition
completely knocks out methylation at this site. It would be interesting to see whether this
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SNP affect bladder cancer risk.

Methylation%

60

80

-------------------------------------------------------------------

-----------------------------------------------------------

0

20

g
40

-----------------------------------------------------------

-----------------------------------------------

AA

GA
Genotype of rs8038732

GG

Fig. 6 rs8038732 affects methylation level of TTC23

Association of SNP rs8038732 with bladder cancer risk in GWAS study
SNP rs8038732 was not genotyped in our previously published genome-wide
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association study (GWAS) [115]. However, we found that another SNP, rs1377267 (A>C),
on the GWAS chip is in strong linkage disequilibrium (r2=0.85) with rs8038732 (Table
13).
Table13 rs8038732 is in high LD with rs1377267
SNP

Linked

Distance

R-Squared

Chromosome

Coordinate_HG18

rs8038732

rs1377267

29908

0.85

chr15

97557412

The SNP rs1377267 was significantly associated with bladder cancer risk in our
GWAS study. Specifically, the OR for individuals carrying one copy of the variant allele
(C) was 1.34 (95% CI, 1.09–1.65), and for those carrying two copies was 0.78 (95% CI,
0.59–1.03). (Table 14)
Table14 Association of rs1377267 and bladder cancer risk
Genotype

Case

Control

OR (95% CI)

P

AA

306

341

1 Ref

AC

528

426

1.34(1.09-1.65)

0.005

CC

135

190

0.78(0.59-1.03)

0.086

rs1377267(A>C)

The association was also similar in superficial (Table 15) and invasive bladder cancer
(Table 16).
Table 15 Association of rs1377267 and cancer risk in NMIBC patients
Genotype

NMIBC

Control

OR (95% CI)

P

AA

154

341

Ref

AC

278

426

1.42(1.11-1.83)

0.005

CC

65

190

0.73(0.52-1.05)

0.089

rs1377267 (A>C)
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Table 16 Association of rs1377267 and cancer risk in MIBC patients
Genotype

MIBC

Control

OR (95% CI)

P

AA

128

341

Ref

AC

218

426

1.28(0.98-1.69)

0.06

CC

55

190

0.76(0.52-1.11)

0.15

rs1377267 (A>C)

From this result, we could infer that rs8038732 has similar association with the risk of
bladder cancer: the heterozygous allele change (GA) increases the bladder cancer risk
significantly. The homozygous variant genotype (AA) is protective for bladder cancer
risk, although the association is not statistically significant.
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DISCUSSION
DNA methylation is one of the most common epigenetic alterations that associate
with cancer development and progression [131]. Meanwhile, DNA methylation detection
is relatively easy due to PCR based methods, which can compensate for the low content
limitation, suggesting that methylation of circulating DNA may be a promising biomarker
for cancer detection [93, 94, 128, 132].

In this study, 396 hypermethylated CpG sites were identified by Illumina
HumanMethylation450 beadchip array. We selected 5 of the candidate CpG sites for
individual validation by pyrosequencing. Successful methylation data were obtained for 4
of the selected CpG sites, located in genes of TTC23, WWOX, ZNF624 and
LOC2211122. Unfortunately, none of these 4 sites exhibited differential methylation
between cases and controls in this validation. To date, pyrosequencing has been a method
with high specificity for DNA methylation analysis [128]. In our study, the
pyrosequencing was performed with 25 ng of bisulfite-modified starting DNA, and all the
results passed the quality controls. For the whole genome DNA methylation profiling, we
started with 1 µg circulating cell free DNA from 1 ml of serum samples. After the
bisulfite treatment, ~250 ng bisulﬁte -converted DNA was loaded to the Illumina
HumanMethylation450 beadchip. There might be two reasons that we could not validate
the primary screening results. First, the data from Illumina HumanMethylation450
beadchip array are not as accurate as pyrosequencing due to the low amount of input
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DNA. Second, the sample size of the primary screening was small (23 samples) and there
was high likelihood of false positives for the top statistically significant hits. It is fairly
common that in large scale genetic and epigenetic biomarker studies, the validated
biomarkers are not among the very top hits during the primary screening. In the future,
we need to enlarge the sample size of primary screening and meanwhile select more
candidate CpG sites for validation. Nevertheless, our study is the first to use Illumina
HumanMethylation450 beadchip to profiling circulating cell free DNA, whereas previous
studies have all used genomic DNA from tissue or peripheral blood. [124, 128, 133-135]
Our study supports the feasibility of genome-wide CpG methylation profiling and
validation of circulating cell-free DNA for the identification of early detection markers.

Interestingly, there was a SNP rs8038732 (G>A) in the methylation site of gene
TTC23.

The

GG

genotype

showed

near

complete

methylation

(Mean

of

Methylation%=92.6), GA heterozygotes half methylation (Mean of Methylation%=43.4),
and AA complete loss of methylation Mean of Methylation%=1.9).

This SNP is clearly

a functional SNP because the G>A transition completely knocks out methylation at this
site. It was reported that altered DNA methylation could suppress tumor suppressor genes
or activate oncogenes, thus initiate tumorigenesis and promote the progression of cancer
[136]. Therefore, it would be interesting to see whether this SNP affects the risk of
bladder cancer. Fortunately, we have data from our previously published GWAS of
bladder cancer.

Even though this specific SNP was not genotyped the GWAS [115], we
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found another SNP rs1377267 (A>C), on the GWAS chip that is in strong linkage
disequilibrium (r2=0.85) with rs8038732. We then analyzed the associations of SNP
rs1377267 with bladder cancer risk in the GWAS study of 969 bladder cancer cases and
946 controls. The SNP rs1377267 turned out to be significantly associated with bladder
cancer risk. Specifically, the heterozygous alleles (AC) was associated with higher
bladder cancer risk (OR=1.34, 95% CI=1.09-1.65), whereas the homozygous alleles (CC)
was marginally associated with lower risk of bladder cancer (OR=0.78, 95% CI=
0.59-1.03). Since this SNP is highly linked with our interested SNP, we could infer that
rs8038732 has similar association with the risk of bladder cancer.

The SNP rs8038732 is located in the intron region of the TTC23 gene, which was
reported as a proto-oncogene. The TTC23 protein was also named Cervical Cancer
Proto-Oncogene 8 Protein. A previous paper showed that TTC23 is a functional target
gene of the BACH1 transcription factor, which is involved in the oxidative stress
response and in cell cycle control [137]. In our study, individuals with the GA genotype
had half methylation and higher bladder cancer risk; but individuals with the AA
genotype who almost completely lost methylation had reduced risk of bladder cancer.
One potential explanation for this observation is that the carcinogenesis is promoted by
medium expression of oncogene TTC23, whereas cell death is induced by overexpression
of TTC23 (Figure 7).
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Fig. 7 Potential mechanism: overexpression of TTC23 could induce cell death

In general, oncogene is believed to promote carcinogenesis through increasing
cell proliferation and survival.

However, there has been evidence showing that

oncogenes have anti-survival characteristics and contribute to tumor suppression. For
instance, Ras was one of the first identified human proto-oncogenes. Ras is a
membrane-anchored protein, which plays an important role in regulating cell
differentiation, growth and apoptosis [138-145]. A study published in 1983 found the
expression of Ras induced growth arrest in fibroblasts, which was one of the first
indications that Ras may have dual functions in cell growth [145, 146]. Subsequent
studies have shown that whether Ras signaling plays either a pro-apoptotic or a
pro-growth role depends on the balance between the selectively deactivated or activated
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downstream pathways [145]. The active overexpression of Ras was also reported to
induce autophagic cell death [147]. Therefore, our observation that the TTC23 may be a
risk or protective factor for bladder cancer etiology is consistent with these previous
observations.
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CONCLUSION
This study shows the feasibility of performing genome-wide CpG methylation
profiling of ctDNA as a tool to screening biomarkers for bladder cancer early detection.
A serendipitous observation was that a SNP rs8038732 in a CpG site of TTC23 is
significantly associated with bladder cancer risk. This CpG-SNP affects local DNA
methylation which, in turn, may affect gene expression and increase bladder cancer risk.
Our data suggest that the abrogation of CpG dinucleotide, which is the site of DNA
methylation, is a potential mechanism through which rs8038732 affects the risk of
bladder cancer.
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